Mupirocin Indications
Mupirocin is FDA-approved for topical treatment of impetigo caused by Staphylococcus aureus and Streptococcus pyogenes, and is also indicated for intranasal decolonization of S. aureus (including MRSA) carriers prior to surgery as part of infection control programs. 1
Primary FDA-Approved Indication
Topical treatment of impetigo caused by:
- Staphylococcus aureus (including MRSA)
- Streptococcus pyogenes
The 2% ointment formulation is applied directly to infected skin lesions 1. Recent evidence confirms excellent efficacy, with 99.2% therapeutic response rates in treating superficial wounds infected with these pathogens 2.
Nasal Decolonization for Surgical Prophylaxis
Pre-operative S. aureus decolonization is a critical indication, particularly in high-risk surgical patients:
- Recommended regimen: 2% mupirocin calcium ointment, 0.5g inserted into each nostril twice daily for 5 days (10 doses total) 3
- Timing: Administer approximately 3 weeks before scheduled surgery when possible 4
Evidence for Surgical Decolonization:
The 2024 European guidelines 5 demonstrate that mupirocin-based decolonization reduces S. aureus surgical site infections (SSIs):
- In orthopedic surgery, targeted decolonization reduced S. aureus SSI rates from 1.3% to 0.3% 6
- Perl et al. showed S. aureus hospital-acquired infections decreased from 7.7% to 4.0% (OR 0.49, p=0.02) with mupirocin decolonization 5
- The 10-dose regimen is superior to 6-dose regimens, maintaining decolonization for at least 4 weeks post-surgery (89.5% vs 68.0%, p=0.016) 4
Surgical specialties where decolonization is most beneficial:
- Orthopedic procedures (especially joint arthroplasties)
- Cardiovascular surgery
- Neurosurgery
- Any procedure involving prosthetic implants
Prevention of Recurrent Skin Infections
For patients with recurrent skin abscesses or furunculosis, the 2014 IDSA guidelines 7 suggest:
- Monthly regimen: Intranasal mupirocin twice daily for 5 days each month (based on older trials)
- Combined decolonization: 5-day course of twice-daily intranasal mupirocin PLUS daily chlorhexidine or dilute bleach baths (¼-½ cup bleach per full bath)
Important caveat: Evidence for preventing recurrent MRSA skin infections in the current era is mixed. One randomized trial in military personnel showed intranasal mupirocin alone did NOT reduce subsequent skin infections in MRSA nasal carriers 7. The combination approach with chlorhexidine bathing may be more effective, though data remain sparse.
Other Skin and Soft Tissue Infections
Mupirocin demonstrates activity against various staphylococcal and streptococcal skin infections 8:
- Secondary wound infections
- Minor traumatic wounds
- Post-surgical wound infections
- Staphylococcus epidermidis and S. saprophyticus infections 1
Critical Dosing Distinction
Do NOT use 6-dose regimens for decolonization—they are inferior to the standard 10-dose (5-day, twice-daily) regimen for maintaining decolonization 4.
Resistance Considerations
- Low-level resistance (MIC 8-256 mg/L): Point mutation in bacterial enzyme; may initially respond but recolonization is common 9
- High-level resistance (MIC ≥512 mg/L): Mediated by mupA gene; treatment failure expected 9
- Risk factors for resistance: Unrestricted over-the-counter use, treatment of chronic wounds/pressure sores, prolonged or repeated courses 9
Restrict mupirocin use to approved indications to minimize resistance development. Avoid using for chronic wound care or pressure ulcers where resistance emergence is strongly associated with overuse 9.
Contraindications and Adverse Effects
Adverse effects are uncommon (incidence similar to placebo) 5: